IP Library Granted Patent US 7,534,814
Granted Patent B2
US 7,534,814 · App. 10/867,232 · Granted May 19, 2009

Mutilin derivatives and their use as antibacterials

Assignee: Nabriva Therapeutics AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,534,814
App. No.
10/867,232
Granted
May 19, 2009
Kind
B2
Abstract

A compound of formula wherein R 2 is arylene or heterocyclene; or R and R 2 together with the nitrogen atom to which they are attached form non-aromatic heterocyclene; and the other residues have various meanings, useful as pharmaceuticals, e.g. antimicrobials.

Claims (40)

1. A compound of formula

wherein

R is hydrogen or alkyl;

R 1 is hydrogen or a group of formula

wherein

X is sulphur, oxygen, NR 10 , wherein R 10 is hydrogen or alkyl, or N + (R′ 10 ) 2 wherein

R′ 10 is alkyl in the presence of an appropriate anion;

R 9 is amino, alkyl, aryl, heterocyclyl or mercapto; and, if X is oxygen, R 9 is additionally hydrogen;

R 2 is phenylene;

R 4 is hydrogen or alkyl;

R 5 is hydrogen or alkyl; and

R 3 , R 3 ′, R 6 , R 7 and R 8 independently of each other are hydrogen or deuterium.

2. A compound of formula I as defined in claim 1 wherein

R is hydrogen;

R 1 is hydrogen or a group of formula

wherein X is sulphur, oxygen, NR 10 , wherein R 10 is hydrogen or alkyl, or N + (R′ 10 ) 2

wherein R′ 10 is alkyl in the presence of an appropriate anion;

R 9 is amino, alkyl, heterocyclyl or mercapto; and, if X is oxygen, R 9 is additionally hydrogen;

R 2 is phenylene;

R 4 is hydrogen or alkyl;

R 5 is hydrogen;

R 3 and R 3 ′ are hydrogen; and

R 6 , R 7 and R 8 are hydrogen or deuterium.

3. A compound according to claim 1 in the form of a salt, or in the form of a salt and in the form of a solvate, or in the form of a solvate.

4. A compound of formula

wherein R 1s is hydrogen or a group of formula

wherein R 6s is hydrogen or deuterium;

R 2s is hydrogen, methyl or tert-butyl;

R 7s is hydrogen or methyl; and

R 3s , R 4s and R 5s are hydrogen or deuterium.

5. A compound which is selected from the group consisting of

14-O-(3-amino)phenyl-sulfanylacetyl)-mutilin;

14-O-(3-amino)phenyl-sulfanylacetyl)-2,2,4-trideutero-mutilin;

14-O-(3-(piperidin-2-yl-carbonylamino)-phenyl-sulfanylacetyl)mutilin;

14-O-(3-(piperidin-2-yl-carbonylamino)-phenyl-sulfanylacetyl)-2,2,4-trideutero-mutilin;

14-O-(3-(piperidin-2-yl-carbonylamino)-2,5-dimethyl-phenylthio-methylcarbonyl)mutilin;

14-O-(3-(piperidin-2-yl-carbonylamino)-2,5-dimethyl-phenylthio-methylcarbonyl)-2,2,4-trideutero-mutilin;

14-O-(3-(piperidin-2-yl-carbonylamino)-5 -tert.butyl-phenyl-sulfanylacetyl)mutilin; and

14-O-(3-(piperidin-2-yl-carbonylamino)-5-tert.butyl-phenyl-sulfanylacetyl)-2,2,4-trideutero-mutilin.

6. A pharmaceutical composition comprising a compound of claim 1 in free form or in the form of a pharmaceutically acceptable salt in association with at least one pharmaceutical carrier or diluent.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA AND THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 062881 FRAME: 0090. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
RELEASE OF SECURITY INTEREST Recorded Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037455/0436 →
SECURITY INTEREST Recorded Aug 28, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033647/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2008
From: SANDOZ GMBH
To: NABRIVA THERAPEUTICS AG
Reel/Frame 021380/0209 →
CHANGE OF NAME Recorded Apr 6, 2007
From: BIOCHEMIE GESELLSCHAFT M.B.H. (AKA BIOCHEMIE GMBH)
To: SANDOZ GMBH
Reel/Frame 019132/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2007
From: ASCHER, GERD; BERNER, HEINZ; HILDEBRANDT, JOHANNES
To: BIOCHEMIE GESELLSCHAFT M.B.H.
Reel/Frame 018955/0941 →
Priority Claims (1)
GB 9918037.4 · Jul 30, 1999 · national
Continuity (2)
Division 1004843800
Related Publication 20040235910A1 · Nov 25, 2004